THUNDER-2 used early tumor regression to guide adaptive rectal cancer dose escalation
ERI-guided escalation to 60.1 Gy produced a 21.9% complete response rate in patients predicted to respond poorly.
Tag
dose-escalation
Dose-escalated chemoradiotherapy improved nine-year survival in locally advanced rectal cancer
A 56 Gy simultaneous integrated boost improved nine-year survival and disease control compared with standard 50 Gy chemoradiotherapy.
FDG-PET-guided dose escalation did not improve control in advanced oropharyngeal and laryngopharyngeal cancers
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.